Patient P-01429
Therapy response
Stable
Tolerance
Stable
GI state
Stable
Inflammatory state
Stable
Nutritional resilience
Improving
Discontinuation risk
56%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S09
- Day 49 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 60 GI-04 recommended — GI Support Protocol GI-04
- Day 61 Patient accepted — Started GI-04 in the companion
- Day 69 GI symptom burden −32% vs expected — GI Support Protocol GI-04
- Day 75 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 49.
Primary contributors, last 14 days
- Nutritional resilience+8
- Inflammatory activity-3
- Toxicity-2
What helped?
- GI Support Protocol GI-04Day 60Result: symptom burden −32%
LIFE OS recommendation
Dietary Support Protocol NP-02
55%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 66% showed improvement
- median effect visible after 10 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 33/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↓65
- WearableResting HR 75 bpm
- Wearable2,095 steps/day
- WearableShort sleep window
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 42
- Inflammatory signalling ↓40
- BloodInflammatory load index 55
- WearableHRV 26 ms, trending down
- Mucosal barrier integrity ↓30
- Daily logGI symptom score 53 and rising
- WearableSleep 5.5 h, below personal baseline
DNA
Fictional pharmacogenomic panel
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 2.8 · butyrate capacity 33/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 30 ms
- Sleep
- 6.0 h
- Steps
- 1,881
- Resting HR
- 76 bpm
Daily log: GI score 53, nutritional resilience 45, adherence 49.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01409 | 58% | S14 | SC-12 | improved | 41 |
| P-01556 | 53% | S14 | GI-04 | improved | 44 |
| P-01573 | 52% | S14 | GI-04 | improved | 49 |
| P-01709 | 52% | S14 | GI-04 | improved | 43 |
| P-01336 | 51% | S03 | GI-04 | improved | 51 |
| P-01431 | 51% | S14 | GI-04 | improved | 41 |
| P-01661 | 51% | S03 | GI-04 | improved | 52 |
| P-01834 | 51% | S14 | NP-02 | improved | 44 |
| P-01330 | 50% | S14 | GI-04 | improved | 47 |
| P-01447 | 50% | S15 | GI-04 | improved | 44 |
| P-01462 | 50% | S14 | NP-02 | improved | 47 |
| P-01496 | 50% | S14 | SC-12 | improved | 46 |